Celanese (CE) Q1 2025 earnings summary

Executive summary

• Q1 2025 net sales were $2.39B–$2.4B, up 1% sequentially but down 9% year-over-year, with a net loss of $21M and adjusted EPS of $0.57, exceeding guidance.

• Operating profit was $168M, with operating EBITDA of $414M and margins of 7%–17%.

• Strategic focus is on cash generation, deleveraging, cost reductions, and operational improvements, including a 95% dividend cut and no share repurchases.

• Major refinancing included $2.55B–$2.6B in note offerings and $1.1B in tender offers, improving debt maturity profile.

• Announced intent to divest Micromax® and other assets to support deleveraging and strategic focus.

Financial highlights

• Q1 2025 adjusted EPS was $0.57, above guidance of $0.25–$0.50; free cash flow was ($73M), outperforming the guided ($300M) outflow.

• FY 2025 free cash flow is targeted at $700M–$800M, up from $498M in 2024, supported by inventory reduction, lower CapEx, and reduced cash taxes.

• Operating EBITDA for 2024 was $2.4B, with a 7% CAGR since 2012.

• SG&A and R&D costs have been reduced by $100–$150M, with $80M in SG&A cuts in January 2025 and $40M more targeted.

• Cash and cash equivalents stood at $951M as of March 31, 2025; total debt was $12.4B–$12.78B.

Outlook and guidance

• Q2 2025 adjusted EPS guidance is $1.30–$1.50, with tailwinds from cost savings, operational improvements, and volume recovery in automotive.

• FY 2025 free cash flow expected to rise 40–60% year-over-year, with confidence in achieving $700M–$800M even if demand weakens.

• Capital expenditures for 2025 are projected at $300–$350M, focused on maintenance and productivity.

• Full-year earnings visibility remains limited due to tariff and global trade uncertainties.

• Deleveraging remains a priority, with further cash conservation and potential asset sales under evaluation.